Advertisement
EDIT vs VYGR
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Voyager Therapeutics (VYGR) Stock Comparison
Key Takeaways
- EDIT has shown positive momentum in recent weeks, boosted by regulatory clearance to begin its first-in-human trial for lead gene-editing candidate EDIT-401, while VYGR has experienced sharp declines amid a leadership transition and technical selling pressure.
- Both are clinical-stage biotechs with no approved products, meaning their valuations hinge heavily on pipeline catalysts and cash runway rather than current profitability.
- EDIT is concentrated on in vivo gene editing for cardiovascular disease, whereas VYGR is focused on gene therapies and antibody programs for neurological conditions such as Alzheimer's disease.
- EDIT recently received an analyst upgrade (Wells Fargo to Overweight), while VYGR retains a "Strong Buy" consensus despite weak near-term price performance.
- Relative performance diverged sharply: EDIT has risen year to date, while VYGR has fallen roughly 55% over the same period.
- Explore more on each ticker: EDIT Major News and EDIT Today's Price Move, plus VYGR Major News and VYGR Today's Price Move.
- For automated market analysis, explore Trending AI Robots to see which trading bots are currently best suited to market conditions.
Introduction
This stock comparison examines Editas Medicine (EDIT) and Voyager Therapeutics (VYGR), two clinical-stage biotechnology companies in the gene-editing and gene-therapy space. Although both operate in the broader "genetic medicine" arena, they target different diseases, use different technologies, and have followed markedly different market trajectories in recent months. For investors and traders weighing high-risk, catalyst-driven biotech exposure, understanding their relative performance, market positioning, and risk profiles can help clarify which name better fits a given strategy. Neither company currently generates meaningful product revenue, so both stories center on pipeline progress, cash runway, and sentiment shifts around clinical milestones.
EDIT Overview and Recent Performance
Editas Medicine is a pioneer in CRISPR (clustered regularly interspaced short palindromic repeats) gene editing, developing one-time, in vivo therapies that edit genes inside the body. After discontinuing its prior reni-cel program in late 2024, the company refocused on EDIT-401, an experimental gene-editing medicine designed to durably lower LDL (low-density lipoprotein, or "bad" cholesterol) by editing the LDLR gene. In recent weeks, EDIT received Australian regulatory and ethics approval to begin the Phase 1/2 "Strive" trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia (HeFH), an inherited high-cholesterol disorder.
That milestone sparked renewed investor interest: Wells Fargo upgraded the stock to Overweight with a $6 price target, and shares have gained roughly 37% year to date. The company reported narrower-than-expected quarterly losses and held about $211.6 million in cash as of mid-2026, a runway it projects will fund operations into the second half of 2028. Momentum has been uneven at times, but the combination of a clear clinical catalyst and an improved balance sheet has supported relatively firmer sentiment.
VYGR Overview and Recent Performance
Voyager Therapeutics develops gene therapies and antibody programs for neurological diseases, leveraging its TRACER platform, which identifies delivery vehicles that can cross the blood-brain barrier, and its NeuroShuttle delivery system. Its pipeline includes VY7523, an anti-tau antibody for Alzheimer's disease, and VY1706, an AAV (adeno-associated virus) gene therapy for Alzheimer's. The company also holds partnerships with larger drugmakers including Novartis and Neurocrine Biosciences.
Despite a "Strong Buy" consensus rating and price targets ranging from $8 to $25, VYGR's stock has fallen sharply in recent weeks, declining roughly 35% over the past month and about 55% year to date. The pullback coincided with a CEO succession announcement and broader concerns about the addressable Alzheimer's population and dosing characteristics flagged in analyst commentary. Quarterly collaboration revenue has declined as partner programs transitioned, and the company posted a net loss in its latest reported quarters, though it maintains roughly $171.7 million in cash, expected to support operations into 2028.
Trending AI Robots
Tickeron's Trending AI Robots page curates a select group of algorithmic trading bots from a broader library of hundreds of AI-driven systems that trade thousands of tickers. Because market conditions change, only the bots whose strategies, timeframes, and statistics are currently best aligned with the prevailing environment earn a place in this featured section. Each bot operates with its own trading style, performance history, and set of covered securities, giving users a range of approaches rather than a single one-size-fits-all signal. For traders comparing names like EDIT and VYGR, these tools offer an alternative, data-driven lens on momentum and positioning. To see which strategies are currently leading, visit the Trending AI Robots page.
Head-to-Head Comparison
EDIT and VYGR diverge across nearly every core dimension. On business model, EDIT is centered on proprietary CRISPR-based in vivo editing with a single lead program aimed at a large cardiovascular market, while VYGR operates a broader platform spanning gene therapy, antibodies, and partnered programs across neurological diseases. Growth drivers differ as well: EDIT's near-term story rests on first-in-human data for EDIT-401, whereas VYGR depends on a mix of internal clinical readouts and partner milestone economics.
Momentum is the starkest contrast. EDIT has exhibited constructive trend behavior and analyst upgrades in recent weeks, while VYGR has broken below key moving averages and sits in a downtrend despite favorable analyst price targets. On risk, both face binary clinical and regulatory outcomes and rely on cash to reach their next milestones; VYGR adds execution uncertainty around a leadership transition, while EDIT carries concentration risk in a single lead asset. Sector exposure overlaps in biotechnology, but EDIT's cardiovascular focus and VYGR's central nervous system (CNS) emphasis expose them to different therapeutic-competition and reimbursement dynamics.
Tickeron AI Verdict
Based on observable factors—trend consistency, relative momentum, balance-sheet positioning, and the timing of catalysts—Tickeron's AI would likely favor EDIT over VYGR in the current environment. EDIT's combination of a recent regulatory clearance, a supportive analyst revision, and firmer year-to-date price behavior suggests more constructive near-term positioning. VYGR's high consensus price targets reflect long-term potential, but its persistent downward trend, leadership change, and softer revenue trajectory weigh on short-term stability. This assessment is probabilistic rather than definitive and reflects current data rather than a forward-looking recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and VYGR is a Hold.
EDIT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for VYGR turns positive, indicating new upward trend
VYGR saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 85 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VYGR's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 61 cases where VYGR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for VYGR just turned positive on October 30, 2026. Looking at past instances where VYGR's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +15.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.744) is normal, around the industry mean (3.498). P/E Ratio (-1.030) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT | VYGR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 47 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 58 | 85 | |
P/E GROWTH RATING 1..100 | 30 | 12 | |
SEASONALITY SCORE 1..100 | 85 | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VYGR's Valuation (47) in the Biotechnology industry is in the same range as EDIT (53). This means that VYGR’s stock grew similarly to EDIT’s over the last 12 months.
VYGR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that VYGR’s stock grew similarly to EDIT’s over the last 12 months.
VYGR's SMR Rating (98) in the Biotechnology industry is in the same range as EDIT (99). This means that VYGR’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's Price Growth Rating (58) in the Biotechnology industry is in the same range as VYGR (85). This means that EDIT’s stock grew similarly to VYGR’s over the last 12 months.
VYGR's P/E Growth Rating (12) in the Biotechnology industry is in the same range as EDIT (30). This means that VYGR’s stock grew similarly to EDIT’s over the last 12 months.
| EDIT | VYGR | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 84% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 83% |
| Declines ODDS (%) | 10 days ago 90% | 13 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- VYGR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 2 TA indicator(s) are bullish while VYGR’s TA Score has 6 bullish TA indicator(s).
- EDIT’s TA Score: 2 bullish, 7 bearish.
- VYGR’s TA Score: 6 bullish, 2 bearish.
Price Growth
EDIT (@Biotechnology) experienced а -3.65% price change this week, while VYGR (@Biotechnology) price change was -0.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
EDIT is expected to report earnings on Feb 25, 2027.
VYGR is expected to report earnings on Mar 09, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EDIT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | -8.91% | ||
| BEAM - EDIT | 67% Closely correlated | -6.92% | ||
| PRME - EDIT | 63% Loosely correlated | -9.30% | ||
| CRSP - EDIT | 63% Loosely correlated | -9.77% | ||
| SLDB - EDIT | 62% Loosely correlated | +2.14% | ||
| VYGR - EDIT | 61% Loosely correlated | -8.29% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FENY | 34.05 | 0.14 | +0.41% |
| Fidelity MSCI Energy Index ETF (FENY) | |||
| MAYZ | 35.57 | N/A | N/A |
| TrueShares Structured Outcome (May) ETF (MAYZ) | |||
| ZECP | 38.66 | -0.02 | -0.05% |
| Zacks Earnings Consistent Portfolio ETF (ZECP) | |||
| SNOV | 27.84 | -0.01 | -0.05% |
| FT Vest U.S. Small Cap Moderate Buffer ETF - November (SNOV) | |||
| PLU | 3.00 | -0.05 | -1.48% |
| Defiance Daily Target 2x Long PL ETF (PLU) | |||